# Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

> **NCT03010982** · PHASE1 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Lymphoma
- Mantle-Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Advanced Solid Tumors

## Interventions

- **DRUG:** Tazemetostat and [14C] Tazemetostat

## Key facts

- **NCT ID:** NCT03010982
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-01-08
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03010982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03010982, "Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03010982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*